MedTrace Logo

Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer

NCT01281943 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-07-04

No results posted yet for this study

Summary

This Phase II study will use the MTD from a previous Phase I study at the recommended dose for the combination regimen from the Phase I trial, Doxil 25mg/m2 IV Q 4 weeks and temsirolimus 25mg IV Q week.

Conditions

  • Liver Neoplasms

Interventions

DRUG

Temsirolimus 25mg and Pegylated liposomal doxorubicin 25mg/m2

Temsirolimus 25mg IV on days 1, 8, 15 and 22 of each 28 day cycle Pegylated liposomal doxorubicin 25mg/m2 IV on day 1 of each 28 day cycle

Sponsors & Collaborators

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • A. Craig Lockhart, M.D. · Washington University School of Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2012-07-31
Completion
2014-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01281943 on ClinicalTrials.gov